Tag: CureVac

Shareholders of the Tübingen-based biotech firm CureVac are approaching a decisive moment. An extraordinary general meeting scheduled for Tuesday, November ...

The future of CureVac as an independent entity now rests in shareholders' hands as a decisive vote approaches. Investors will ...

The independent existence of CureVac could soon be a chapter in corporate history. On November 25, shareholders will convene in ...

The fate of German biotech firm CureVac hangs in the balance as shareholders prepare for a landmark decision that could ...

The acquisition drama surrounding German biopharmaceutical firm CureVac approaches its climax as investors prepare for a landmark shareholder vote. With ...

The proposed multi-billion euro acquisition of CureVac by BioNTech enters its final phase with two crucial November deadlines approaching. Shareholders ...

CureVac investors face a pivotal moment as BioNTech's acquisition proposal moves toward a decisive shareholder vote. The extraordinary general meeting ...

The biotechnology sector is watching closely as BioNTech's proposed acquisition of CureVac enters its decisive phase. With a November 25 ...

The proposed acquisition of CureVac by BioNTech is accelerating toward its final stages. CureVac investors face a pivotal decision on ...

The fate of CureVac hangs in the balance as shareholders approach a critical decision point regarding BioNTech's acquisition proposal. With ...